VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis
Objectives-Methods. Visceral leishmaniasis (VL) is characterized by chronicity and relapses despite efficacious treatment. Acute and chronic inflammatory processes and concomitant disturbances in cell adhesion characterize the pathogenesis of the disease. To investigate these processes further we me...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2017-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2765 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850215922018549760 |
|---|---|
| author | Alexandros Makis Sophia Tsabouri Paraskevi Karagouni Maria Rogalidou Irene Sionti Nikolaos Chaliasos |
| author_facet | Alexandros Makis Sophia Tsabouri Paraskevi Karagouni Maria Rogalidou Irene Sionti Nikolaos Chaliasos |
| author_sort | Alexandros Makis |
| collection | DOAJ |
| description | Objectives-Methods. Visceral leishmaniasis (VL) is characterized by chronicity and relapses despite efficacious treatment. Acute and chronic inflammatory processes and concomitant disturbances in cell adhesion characterize the pathogenesis of the disease. To investigate these processes further we measured adhesion molecules (L-selectin, ICAM-1 and VCAM-1) serum levels in 16 children with VL, as well as in 20 healthy controls. All children were treated with liposomal amphotericin B (3 mg/kg) on days 1 to 5, 14, and 21. Measurements were performed at days 0, 15 and 30. Results. All children responded well to treatment in both clinical and laboratory terms. In three cases relapse occurred at 3, 5 and 6 months after treatment had ended. Serum L-selectin levels, both pre-treatment and post-treatment, did not significantly differ between patients and controls. VCAM-1 and ICAM-1 median levels were similar in patients and controls (P>0.05) at day 0 and significantly increased at day 15 (P<0.05). Interestingly, VCAM-1 and ICAM-1 dropped at day 30, with median levels comparable to those before treatment in the 13 children who subsequently had a good outcome without relapses (P>0.05), but not in the 3 patients who relapsed (P<0.05). Conclusions. Despite the small number of the patients, the changes in VCAM-1 and ICAM-1 levels indicate the anti-parasite activation of the immune system during the course of VL and the effect of treatment. Decline in post-treatment serum VCAM-1 and ICAM-1 levels might be used as a marker of treatment efficacy in childhood VL. |
| format | Article |
| id | doaj-art-2957d9cd20db492b8595922609dcd2e9 |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-2957d9cd20db492b8595922609dcd2e92025-08-20T02:08:27ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062017-01-0191e2017011e201701110.4084/mjhid.2017.0111657VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasisAlexandros Makis0Sophia TsabouriParaskevi KaragouniMaria RogalidouIrene SiontiNikolaos ChaliasosAssistant Professor in Paediatrics/Paediatric Haematology, Child Health Dept., University of Ioannina Medical School, GREECEObjectives-Methods. Visceral leishmaniasis (VL) is characterized by chronicity and relapses despite efficacious treatment. Acute and chronic inflammatory processes and concomitant disturbances in cell adhesion characterize the pathogenesis of the disease. To investigate these processes further we measured adhesion molecules (L-selectin, ICAM-1 and VCAM-1) serum levels in 16 children with VL, as well as in 20 healthy controls. All children were treated with liposomal amphotericin B (3 mg/kg) on days 1 to 5, 14, and 21. Measurements were performed at days 0, 15 and 30. Results. All children responded well to treatment in both clinical and laboratory terms. In three cases relapse occurred at 3, 5 and 6 months after treatment had ended. Serum L-selectin levels, both pre-treatment and post-treatment, did not significantly differ between patients and controls. VCAM-1 and ICAM-1 median levels were similar in patients and controls (P>0.05) at day 0 and significantly increased at day 15 (P<0.05). Interestingly, VCAM-1 and ICAM-1 dropped at day 30, with median levels comparable to those before treatment in the 13 children who subsequently had a good outcome without relapses (P>0.05), but not in the 3 patients who relapsed (P<0.05). Conclusions. Despite the small number of the patients, the changes in VCAM-1 and ICAM-1 levels indicate the anti-parasite activation of the immune system during the course of VL and the effect of treatment. Decline in post-treatment serum VCAM-1 and ICAM-1 levels might be used as a marker of treatment efficacy in childhood VL.http://www.mjhid.org/index.php/mjhid/article/view/2765Leishmaniasis, adhesion molecules |
| spellingShingle | Alexandros Makis Sophia Tsabouri Paraskevi Karagouni Maria Rogalidou Irene Sionti Nikolaos Chaliasos VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis Mediterranean Journal of Hematology and Infectious Diseases Leishmaniasis, adhesion molecules |
| title | VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis |
| title_full | VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis |
| title_fullStr | VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis |
| title_full_unstemmed | VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis |
| title_short | VCAM-1 and ICAM-1 serum levels as markers of relapse in visceral leishmaniasis |
| title_sort | vcam 1 and icam 1 serum levels as markers of relapse in visceral leishmaniasis |
| topic | Leishmaniasis, adhesion molecules |
| url | http://www.mjhid.org/index.php/mjhid/article/view/2765 |
| work_keys_str_mv | AT alexandrosmakis vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis AT sophiatsabouri vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis AT paraskevikaragouni vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis AT mariarogalidou vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis AT irenesionti vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis AT nikolaoschaliasos vcam1andicam1serumlevelsasmarkersofrelapseinvisceralleishmaniasis |